Relates to Heterocyclic compounds of formula (i) wherein R1 is H, halogen, Nitro, CN, among others R2 is H, halogen, CN, amino, among others R3 is H, halogen, alkyl (C1 - C7), among others R4, R4, R5, R6 and R7 are each H, alkyl (C1 - C7), haloalquilo (C1 - C7) or hidroxialquilo (C1 - C7 is c or e) R8 N h, halogen, Nitro, hydroxyl, among others R9 is H, halogen, alkyl (C1 - C7), Oxo,Among others, R13 and R14 are each h, alkyl, halogen (C1 - C7), cn or hidroxialquilo (C1 - C7) R15 and R16 are each h, Oxo, tioxo, alkyl (C1 - C7) or CN, is a Heterocyclic Ring of 5 to 12 members b is a Heterocyclic Ring of five members.Preferred compounds are: {2 - [5 - (3,4-dichlorophenyl) furan-2 - il] ethyl} amide acid 5 - (1 - piperazin - carbonyl) - 2H - - 3 - pyrazole carboxylic acid n - (2 - (5 - (3,4-dichlorophenyl) furan-2 - il) ethyl) - 3 - (4 - (carbonyl) - 1H pyrazole carboxamide - 5 - (S) - N - (1 - (3 - (4 - cyano - 3-methylphenyl) - 1H pyrazol-1-yl) propan-2-yl) - 3 - (Furan - 2 - il) - 1H pyrazole - 5 - carboxamide among others. It also relates to a Pharmaceutical composition.These compounds are androgen receptor modulators of tissue selective (MRSA) being useful in the treatment of Prostate CancerSE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE R1 ES H, HALOGENO, CN, NITRO, ENTRE OTROS R2 ES H, HALOGENO, CN, AMINO, ENTRE OTROS R3 ES H, HALOGENO, ALQUILO(C1-C7), ENTRE OTROS R4, R4, R5, R6 Y R7 SON CADA UNO H, ALQUILO(C1-C7), HALOALQUILO(C1-C7) O HIDROXIALQUILO(C1-C7) E ES C O N R8 ES H, HIDROXI, HALOGENO, NITRO, ENTRE OTROS R9 ES H, HALOGENO, ALQUILO(C1-C7), OXO, ENTRE OTROS R13 Y R14 SON CADA UNO H, ALQUILO(C1-C7), HALOGENO, CN O HIDROXIALQUILO(C1-C7) R15 Y R16 SON CADA UNO H, OXO, TIOXO, ALQUILO(C1-C7) O CN A ES UN ANILLO HETEROCICLICO DE 5 A 12 MIEMBROS B ES UN ANILLO HETEROCICLICO DE 5 MIEMBROS. SON COMPUESTOS PREFERIDOS: {2-[5-(3,4-DICLOROFENIL)FURAN-2-IL]ETIL}AMIDA DEL ACIDO 5-(PIPERAZIN-1-CARBONIL)-2H-PIRAZOL-3-CARBOXILICO N-(2-(5-(3,4-DICLOROFENIL)FURA
